CClinicalTrials.gg
Not yet recruitingNCT07095179Updated Feb 6, 2026

Effects of Inspiratory Muscle Exercise on Health

An interventional study of Eupnea and Intermittent inspiratory muscle training (IIMT) in Intermittent Inspiratory Muscle Training and Eupnea, sponsored by National Taiwan Normal University. Not yet recruiting. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by National Taiwan Normal University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to investigate whether inspiratory muscle training has an immediate effect on energy expenditure, heart rate, blood glucose, blood pressure, and arterial stiffness in healthy adults, obese adults, and adults with type 2 diabetes.

Read the detailed description

Participants will be asked to complete two trials involving intermittent exercise, which will include eupnea and inspiratory muscle training (IMT), as well as a resting control condition, in a randomized crossover study design. The trials will be separated by a minimum of 48 hours and will be completed within a 7-day period. Throughout all trials, participants will be required to remain relaxed and seated on an adjustable examination bed. For the IMT intensity, participants will utilize an inspiratory muscle training device (PowerBreathe Plus, Powerbreathe International Ltd., UK) and adjust the resistance to a level at which breathing continuously for 20 breaths is perceived as "somewhat hard" (RPE = 13), according to the Rating of Perceived Exertion (RPE) scale. This will take place during a 3.5-hour oral glucose tolerance test (OGTT). During the trials, participants may watch television or read; however, typing on a laptop or computer will be prohibited.

02

Conditions studied

  • Intermittent Inspiratory Muscle Training
  • Eupnea

Keywords

  • Energy Expenditure
  • Metabolic Health
  • Pulse Wave Velocity
  • Inspiratory muscle training
03

In context

Lead sponsor

National Taiwan Normal University is the lead sponsor of 62 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adults, obese adults and adults with type 2 diabetes
  • Aged between 20 to 45 years
  • Weight stable for more than 3 months (no change in weight +/- 3%)
  • Non-smoker
  • Non-highly trained athletic team members
  • Normal lifestyle patterns

Exclusion criteria

Exclusion Criteria

  • Personal history of/existing hypertension, respiratory infectious disease, cardiovascular disease, metabolic disease
  • Taking medications that may influence lipid or carbohydrate metabolism or immune system function
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Eupnea

    Participants will breathe normally.

    Behavioral: Eupnea

  • Experimental
    Inspiratory muscle training

    Intermittent inspiratory muscle training (IMT) will be conducted throughout the trial

    Behavioral: Intermittent inspiratory muscle training (IIMT)

Interventions

  • BehavioralEupnea

    Participants will breathe normally.

  • BehavioralIntermittent inspiratory muscle training (IIMT)

    Intermittent inspiratory muscle training (IIMT) will be conducted throughout the trial

06

What researchers measure

Primary outcomes

  1. Blood glycaemic responses

    Changes in blood glycaemic responses between trials

    Time frame: 0 (baseline), 30, 60, 120, and 210 minutes during the 210-minute trial

  2. Pulse wave velocity (PWV)

    Changes in pulse wave velocity between trials

    Time frame: 0 (baseline), 30, 60, 90, 150, and 210 minutes during the 210-minute trial

Secondary outcomes

  1. Energy expenditure

    Changes in energy expenditure between trials

    Time frame: First 90 minutes during the 210-minute trial

  2. Heart Rate Variability (HRV)

    Changes in Heart Rate Variability (HRV) between trials

    Time frame: In a regular patterns during the 210-minute trial

  3. Visual analogue scale (VAS)

    Changes in the visual analogue scale (VAS) ranged from 0 to 100 mm, with higher values indicating a greater intensity of sensation between trials.

    Time frame: Every 30 minutes during the 210-minute trial

  4. Perceived stress scale (PSS)

    Changes in perceived stress scale (PSS) with higher values indicating a greater intensity of sensation between trials.

    Time frame: Every 30 minutes during the 210-minute trial

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07095179
Lead sponsor
National Taiwan Normal University
Responsible party
Yung-Chih Chen (Principal Investigator, National Taiwan Normal University) — Principal investigator
First posted
Jul 31, 2025
Start date
Mar 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Yung-Chih Chen, PhD
Contact
yc.chen@ntnu.edu.tw
02-77496979

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion